At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 56 enrolled
Drug / intervention
Drug: GB-102 +1 moredrug
Likely dose
Aflibercept 2 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2b Multicenter Dose-Ranging Study Evaluating the Safety and Efficacy of Sunitinib Malate Depot Formulation (GB-102) Compared to Aflibercept in Subjects With Neovascular (Wet) Age-related Macular Degeneration (ALTISSIMO Study)
In Brief
A Phase 2 clinical trial evaluating Drug: GB-102 and Aflibercept for Neovascular Age-Related Macular Degeneration. Completed, enrolled 56 participants across 33 sites.
Detailed Summary
Phase 2b, multicenter, visual examiner-masked, randomized active-controlled, parallel-arm design study to evaluate the safety and duration of repeated IVT injections of 3 dose levels of GB-102 compared with aflibercept.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
2020202120222023202420252026
First PostedMay 2019
Enrollment StartSep 2019
Primary CompletionDec 2020
Study CompletionJun 2021
TodayJul 2026
First PostedMay 16, 2019
Enrollment StartSep 26, 2019
Primary CompletionDec 15, 2020
Study CompletionJun 3, 2021
TodayJul 2, 2026
Enrollment to primary: 1.2 yearsPosted 7.1 years ago
Interventions
Drug: GB-102drug
Intravitreal injection of GB-102
Afliberceptdrug
Intravitreal injection of aflibercept (2 mg dose)